A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

NCT07792954 · tracked via the Priya Life Science China tracker

Sponsor

Pfizer

Phase

Phase 3

Started

2026-09-01

Last updated

2026-09-04

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

BerobenatidePlacebo

Berobenatide: Solution for injection

Placebo: Solution for injection

Study summary

Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.

The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine.

People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment.

Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur.

During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation.

The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adults ≥18 years of age. * BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity. * Participants with T2D must have HbA1c 6.5% to 10.0%. * At least one prior unsuccessful dietary weight-loss attempt. Exclusion Criteria: * Significant recent weight change (\>5% within 3 months). * Type 1 diabetes mellitus. * History of pancreatitis. * Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2). * Recent bariatric surgery or obesity procedures. * Pregnancy or breastfeeding.

Primary outcome measure(s)

Percent Change From Baseline in Body Weight at Week 48 — Baseline to Week 48

Trial sites (33)

Facility	City	Region
The Second People's Hospital of Hefei	Hefei	Anhui
Peking University People's Hospital	Beijing	Beijing Municipality
Beijing Friendship Hospital	Beijing	Beijing Municipality
Beijing Pinggu Hospital	Beijing	Beijing Municipality
Beijing Tsinghua Changgung Hospital	Beijing	Beijing Municipality
Chongqing People's Hospital	Chongqing	Chongqing Municipality
Chongqing University Three Gorges Hospital	Chongqing	Chongqing Municipality
Huizhou Central People's Hospital	Huizhou	Guangdong
Harrison International Peace Hospital	Hengshui	Hebei
The Second Hospital of Hebei Medical University	Shijiazhuang	Hebei
The Fourth Hospital of Harbin Medical University	Harbin	Heilongjiang
Luoyang First People's Hospital	Luoyang	Henan
The First Affiliated Hospital of Henan University of Science &Technology	Luoyang	Henan
The Second Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan
Shiyan Taihe Hospital	Shiyan	Hubei
Wuhan Third Hospital	Wuhan	Hubei
Changzhou Second People's Hospital	Changzhou	Jiangsu
The Second Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu
Nanjing First Hospital	Nanjing	Jiangsu
Affiliated Hospital of Nantong University	Nantong	Jiangsu
Affiliated Hospital of Jiangsu University	Zhenjiang	Jiangsu
Jiangxi Provincial People's Hospital	Nanchang	Jiangxi
Pingxiang People's Hospital	Pingxiang	Jiangxi
The Second Hospital of Jilin University	Changchun	Jilin
The First Affiliated Hospital of Xi'an Medical University	Xi'an	Shaanxi
Jinan Central Hospital	Jinan	Shandong
Zhongshan Hospital,Fudan University	Shanghai	Shanghai Municipality
Shanghai Tenth People's Hospital	Shanghai	Shanghai Municipality
The Fifth People's Hospital of Shanghai	Shanghai	Shanghai Municipality
Pudong New Area People's Hospital Shanghai	Shanghai	Shanghai Municipality
Hangzhou First People's Hospital	Hangzhou	Zhejiang
The first affiliated hospital of Ningbo university	Ningbo	Zhejiang
Tianjin Medical University General Hospital	Tianjin	China

More Pfizer trials in China

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer Active, not recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) Recruiting

Other trials for the same condition

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

Food Intake-Related Brain and Metabolic Responses in Obesity Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting

An Observational Cohort Study to Obese Patients With Weight Cycling Active, not recruiting

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07792954 on ClinicalTrials.gov ↗ ← All trials in China